Call for Abstracts

Abstract Submission is now closed
Deadline Abstract submission: Monday 05 March 2012 (midnight CET)

Abstract Regulations

With the submission of an abstract to EACR-22, the first author (presenting author):

Accepts responsibility for the accuracy of the submitted abstract.
Confirms that all authors are aware of and agree to the content of the abstract and support the data presented.
Warrants that the data and conclusions presented in the abstract have not been published in the same format and with the same title prior to the date of the conference.
Identifies any financial interest in products or processes described in the abstract. This information is to be forwarded to the Scientific Committee together with the abstract.
States that, for studies involving human or animal subjects, permission has been obtained from the relevant regulatory authority and properly informed consent given where appropriate.
Gives permission for the abstract, when selected for presentation (oral or poster), to be published. Submitted abstracts cannot be withdrawn after 31 March 2012.

Abstract Format

In order to be considered, an abstract should respect the following guidelines:

The abstract must be submitted in good English. The Scientific Committee reserves the right to reject those abstracts, which are presented in poor English, or may request an immediate revision by the presenter.
Abstract titles should be brief and should reflect the content of the abstract.
Commercial names may not be used in the abstract title.
No more than 10 authors can be listed. Only institutional affiliations, cities and countries should follow.
Abstracts should be organised under the headings:
- Introduction
- Material and method
- Results and discussion
- Conclusion
The online abstract submission procedure will not accept abstracts that exceed 2,500 characters (body of the abstract)
Abbreviations may be used if standard or if spelled out and defined at the first use.
Compounds should be mentioned with the generic name, in lower cases. Commercial names are admitted in the text, with an R, and if in brackets following the generic name, i.e." generic (Commercial R)".
Supplementary data or appendices will not be accepted.
Figures or photographs are not allowed. Symbols and structures of drugs are allowed and should be drawn in black.

Only the submitting author will receive a confirmation/abstract number by email from the EACR-22 Conference Secretariat within 48 hours of submission. This confirmation of abstract receipt is NOT a notice of acceptance.

For questions regarding the online submission process please contact Rebekka Mattyasovszky,

Email: rebekka.mattyasovszky<at>ecco.org.eu

*please replace <at> with @

Abstract Selection Process

The Scientific Committee will make the selection of abstracts for oral and poster presentations in March 2012. By early April 2012, the first author (presenter) will receive an email with the result of the review and the Scientific Committee's decision on the abstract.

If a selected author cannot attend, the presenting author should assign a replacement.

The following presentation formats are applicable for EACR-22:

1.	Oral presentation: the abstract is selected for oral presentation in a main programme symposium
2.	Poster: abstracts that have been selected for presentation in poster format. Posters are grouped by topic and will be displayed in the Poster Session during all sessions. A formal Poster Defence Session will be scheduled

Please note that if the oral or poster abstract is accepted, the abstract will only be published in the Abstract Book if one of the authors is a registered participant and full payment has been received by the advised deadline.

Abstract Submission

Abstracts must be submitted online by 05 March 2012, via the ECCO website.

Please follow the instructions on the screen.

Please note:

When finished with the online submission, please click the "FINAL SUBMISSION" button for the final submission of the abstract. As a confirmation of your submission, a message will appear on the screen informing you the abstract has been successfully submitted to our database.
If you need to edit your abstract at a later stage please click "SAVE AND CLOSE". This button allows you to update your abstract before final submission.
After clicking "SAVE AND CLOSE", your abstract is NOT yet submitted. You need to return to the abstract submission page, finalise your abstract and click "FINAL SUBMISSION". If you have not "FINAL SUBMITTED" your abstract by the deadline of 05 March 2012 your abstract can not be accepted.
Within 24 hours of submission, only the presenting author will receive a confirmation by e-mail. This confirmation of abstract submission does not mean your abstract has been selected for presentation.
If you do not receive any confirmation, please contact Rebekka Mattyasovszky (rebekka.mattyasovszky<at>ecco.org.eu) within one week following the submission of the abstract.
Submitting an abstract for EACR-22 does not constitute registration for the conference. Abstract presenters must register to attend EACR22 by following the instructions for registration on the website.

For questions regarding the online submission process, contact rebekka.mattyasovszky<at>ecco.org.eu

*please replace <at> with @

Only abstracts submitted online can be accepted. Abstracts submitted on paper or by email attachment will not be considered.

Topics for Abstract Submission

1. CELL AND TUMOUR BIOLOGY

Cell Proliferation/cell cycle
Cell Death / Autophagy
Oncogenes and Tumour Suppressor Genes
Tumour Progression: Invasion and Metastasis
Metastases and EMT
Tumour Microenvironment
Tumour Angiogenesis
Tumour Immunology AND Inflammation
Aging and Cancer
Senescence
Cancer Cell Metabolism
Cancer Initiating Cells / Cancer Stem Cells
Tumour heterogeneity

2. CANCER GENOMICS, EPIGENETICS and GENOMIC INSTABILITY

Genomic Alterations in Cancer
Functional Genomics
Epigenetic mechanisms and RNA
Genetic instability
Deep sequencing

3. SIGNALING PATHWAYS

Receptors and Signal Transduction
Gene Expression, Transcriptional Regulation
Systems biology
Computational models of biological systems
Omics technologies

4. CARCINOGENESIS

Mutagenesis, Carcinogen Metabolism
Promotion and Progression
DNA Damage and Repair
Viral Oncogenesis

5. TRANSLATIONAL RESEARCH

Organ Site‐Specific Investigations: Preclinical, Diagnosis, Treatment
Molecular pathology
Biomarkers with clinical relevance, imaging
Prognostic biomarkers of therapy response
Prognostic value of oncogenomics
Clinical Phase I/II trials with targeted drugs and novel agents
Bioinformatics in therapies and clinical trials
Animal models of cancer
Infrastructures (biobanks, databases, genomic resources, others)

6. EXPERIMENTAL / MOLECULAR THERAPEUTICS, PHARMACOGENOMICS

Drug Discovery / Drug Design
Novel Targets, Delivery Systems
Mechanisms of Drug Action, Drug Profiling
Drug Resistance
Novel Approaches to Diagnosis of Cancer
New Therapies
Companion diagnostics
Personalized medicine

7. TUMOUR IMMUNOLOGY

Tumour Immunology
Immune Suppression and Escape
Tumor antigens and immune effectors
Immunotherapy and Cancer Vaccines

8. RADIOBIOLOGY / RADIATION ONCOLOGY

Tumour Cell Sensitization to Radiotherapy
Radiation‐activated Signaling Pathways
Cell Cycle and Apoptosis in Radiation Responses
Radiation Oncology; Preclinical and Clinical
Translational radiation research

9. MOLECULAR AND GENETIC EPIDEMIOLOGY

Risk Factors
Biomarkers
Risk Assessment
Susceptibility Genes
Genotype / Phenotype Correlations
Genetic Polymorphisms and Cancer Susceptibility
Epidemiology

10. PREVENTION and EARLY DETECTION

Preclinical Prevention Studies, Markers and Prevention
Clinical Prevention Studies
Vaccination Against Cancer